Autopsy report · NCT00771043

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a

“Sponsor decision to withdraw study at this time.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Biogen

Sponsor type

Industry

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

TYSABRI and AVONEX

Participants

0

Trials that died the same way

• Serum-Free Thymus Transplantation in DiGeorge Anomaly
  “The sponsor decided to withdraw the study.” (90% match in meaning)
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
  “Study withdrawn by Sponsor” (89% match in meaning)
• Consolidation Therapy in Patients With Metastatic Solid Malignancies
  “Sponsor decision to discontinue study.” (89% match in meaning)
• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (88% match in meaning)
• EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
  “Study Withdrawn by Sponsor prior to Enrollment.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.